Note: I am no expert in stock market trading and I currently hold no Allergan (AGN) shares in my portfolio. If I were a bit wealthier, I would seriously consider buying a few hundred shares of the pricey AGN stock.

I have discussed Allergan (of Botox fame) several times on this blog during the past year. The company has had an extremely eventful 2015. In March of this year, it was acquired by Ireland’s Actavis, but the acquiring company then changed its name to Allergan, probably because the latter is so much more widely known than the former.

More importantly for us hair loss sufferers, in June of this year Allergan acquired Kythera Biopharmaceuticals. As a result, Allergan now holds the rights to three potentially blockbuster products (the first two are related to hair loss).

Allergan: Bimatoprost, Setipiprant and Kybella

1. Bimatoprost (prostamide — aka prostaglandin-ethanolamide — analog). This is not exactly a PGE2 analog as is often mistakenly cited on internet forums. Sales will depend on the clinical trial results that I hope will be published any day in the next several months. If effective, I would guess that sales will be drastically higher than lower-dose Bimatoprost products currently sold by Allergan = i.e., Latisse (around $150 million annual sales) and Lumigan (around $600 million annual sales). Maybe $1 billion in 2017 sales if the product really has a better effect than Minoxidil and it is released in 2016? I am just throwing around numbers here so a financial expert can perhaps post comments with better forecasting.
2. Setipiprant (KYTH-105 — selective oral antagonist to the PGD2 receptor). Still several years before clinical trials for hair loss are completed, but numerous other clinical trials for other conditions have been completed on humans with no major side effects. Maybe this pre-existing safety profile will speed up Allergan’s trials, especially in combination with newer regulations from the 21st Century Cures Act. Kythera also submitted an Investigational New Drug Application (IND) for Setipiprant to the US FDA a few weeks ago. If extremely effective, sales would easily hit a few billion dollar per year in say 2020, but this is too much speculation so early in the process. Note: Numerous people on hair loss forums are already testing Setipiprant, but I have not closely followed how they are getting their product and whether its topical or oral. If there are many positive anecdotal reports on this in the next year, I will have to seriously consider borrowing money to buy at least several hundred shares of AGN stock.
3. Kybella^TM (ATX -101 — a patented formulation of deoxycholic acid) injected into the face to eliminate double chins. This product was approved by the FDA in April 2015 and is already in use at 100s of clinics in the US. Unlike the case with Botox, results from Kybella supposedly last for years. Waiting lists are already being created in countries that have not yet been granted licenses to use Kybella. It is worth following realself Kybella reviews to see if the product is all that it is touted to be (keeping in mind fake or flaky reviews). One article I read suggests that Allergan expects annual sales of $500 million for this product in a few years, and the patents on it run out around 2025-2030. However, there are some sources that suggest that that this product could be used for other purposes (love handles?) illegally/with doctor approval too. Is it possible that Allergan can make much more in Kybella sales than they expect? Moreover, it seems like it is fairly simple and cheap to manufacture this Kybella product.

Note: Allergan’s total company sales in the first half of 2015 were $10 billion.

Like many hair loss forum members, I have been much more optimistic about Setipiprant than about Bimatoprost. Clinical trial results of Bimatoprost used at a higher dose on scalp hair have been delayed for many months, although that does not necessarily mean that the results were too weak.

I should note that I have read some positive testimonials about Bimatoprost on hair loss forums, and it is almost impossible that an Allergan representative is posting such testimonials. Hopefully Bimatoprost turns out to be at the very least as effective as Minoxidil, while Setipiprant turns out to be even more effective and capable of growing new hair (or turning vellus hair back into terminal hair).

Is Allergan Preparing to Release Bimatoprost for Hair Loss?

In any event, the main reason for writing this post was because several days ago a member on the Baldtruthtalk forums posted an interesting link regarding Allergan expanding its plant in Waco, Texas. The expansion is due to the addition of new processing equipment for packaging. While the company’s VP of operations declined to name the products for which the packaging would be needed, there is a good chance that it might be for Bimatoprost. The plant already makes weaker versions of Bimatoprost (Latisse and Lumigan). Moreover, the VP of operations said something very interesting:

We will be producing new packaging for new and existing products, and we could see the need to hire more people by the third quarter of 2016 if demand for these products increases.

Blog readers who live in Texas, please go to Waco and do some ground research! Buy one of the workers at this plant lunch and beer to get some inside information. Look around for any paper trails or early arrival of packaging material labeled with anything with the words “Bimatoprost” or “hair” in it.